TABLE 3

Changes in haemodynamic parameters on ambrisentan and placebo between baseline and week 48

All subjectsGroup 3# PH subjects
AmbrisentanPlaceboAmbrisentanPlacebo
Mean±sdnMean±sdnMean±sdnMean±sdn
Change in mean PAP mmHg−1.1±5.99730.4±5.8544−5.3±4.2712−1.1±9.397
Change in cardiac output L·min−10.56±1.4572−0.38±1.30430.03±1.38120.44±0.97
Change in PVR mmHg·L−1·min−0.41±1.19720.14±0.7943−0.70±1.3112−0.51±1.567
  • PH: pulmonary hypertension; PAP: pulmonary arterial pressure; PVR: pulmonary vascular resistance. #: World Health Organization group.